Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06231862 · ClinicalTrials.gov registry record
Gene Expression Objective Definition of Early Sepsis In Children
A clinical trial of Sepsis and Non-Infectious Systemic Inflammatory Response Syndrome, sponsored by Seattle Children's Hospital.
- Completed
- Registry status
- 100
- Enrollment target
- 2
- Study locations
NCT06231862: Completed study of Sepsis and Non-Infectious Systemic Inflammatory Response Syndrome, sponsored by Seattle Children's Hospital.
NCT06231862 is a study of Sepsis and Non-Infectious Systemic Inflammatory Response Syndrome that has completed, run by Seattle Children's Hospital. The registered enrollment target is 100 participants, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06231862, a study of Sepsis and Non-Infectious Systemic Inflammatory Response Syndrome, has completed, sponsored by Seattle Children's Hospital.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
GEODESIC is a prospective descriptive cohort investigation that will examine the generalizability of the novel host gene expression biomarkers, SeptiCyteTM LAB, SeptiCyteTM VIRUS, SeptiCyteTM BACT, and SeptiCyteTM TRIAGE (collectively 18 genes or SeptiCyteTM LVBT) and SeptiCyteTM RAPID, for differentiating children with bacterial sepsis, versus severe viral illness, versus non-infectious related systemic inflammatory response syndrome.
Primary Outcome
SeptiCyte (various) gene expression scores
Conditions Studied
Interventions
- DIAGNOSTIC_TEST SeptiCyte (various)
Study Locations (2)
Washington
- Seattle Children's Hospital, Harborview Medical Center - Seattle
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2023-03-01 |
What the finished NCT06231862 record still lists
NCT06231862 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which SeptiCyte (various) is the first listed.
NCT06231862 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT06231862 about?
NCT06231862 is a clinical study titled "Gene Expression Objective Definition of Early Sepsis In Children". GEODESIC is a prospective descriptive cohort investigation that will examine the generalizability of the novel host gene expression biomarkers, SeptiCyteTM LAB, SeptiCyteTM VIRUS, SeptiCyteTM BACT, and SeptiCyteTM TRIAGE (collectively 18 genes or SeptiCyteTM LVBT) and SeptiCyteTM RAPID, for differen...
What is the current status of trial NCT06231862?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2019-03-01. Estimated completion is 2023-03-01.
What conditions does trial NCT06231862 study?
This clinical trial studies the following conditions: Sepsis, Non-Infectious Systemic Inflammatory Response Syndrome.
What interventions are being tested in trial NCT06231862?
The interventions under investigation include: SeptiCyte (various) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06231862?
This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06231862 being conducted?
This trial has 2 study locations across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06231862's enrollment target sits among peer trials
100 56th of 90 higher than 35 of 90 other Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The APS Phenotyping Study
RECRUITING
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Renin Angiotensin Aldosterone System In Septic Kids
RECRUITING
-
The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls
RECRUITING · NA
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI